1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow Recurrent Oral Cavity Squamous Cell Carcinoma: new trials by email Literature Review of Recurrent Oral Cavity Squamous Cell Carcinoma trials Research Report on Recurrent Oral Cavity Squamous Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment Biospecimen Collection, Cetuximab, Computed Tomography - Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma | Phase 3 | Recruiting | National Cancer Institute (NCI) | 158 | 2025-03-27 | 2026-10-26 |
Carcinoma (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Mouth Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma, Squamous Cell (1) · Head and Neck Neoplasms (1) · Laryngeal Diseases (1) · Mouth Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Otorhinolaryngologic Diseases (1) · Otorhinolaryngologic Neoplasms (1) · Pharyngeal Diseases (1) · Pharyngeal Neoplasms (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Stomatognathic Diseases (1)
(225)Ac-DOTA-c(RGDyK) (1) · Cetuximab (1) · Magnetic Resonance Spectroscopy (1) · Specimen Handling (1) · pembrolizumab (1)
National Cancer Institute (NCI) (1)
United States (1)
Siddharth Sheth (1)
U10CA180821 (1)